Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2019 | Predicting MM response to cellular and immunotherapies

Paola Neri • 17 May 2019
COMy 2019
Multiple Myeloma Antibodies CAR-T Checkpoint inhibitors Daratumumab

Paola Neri, MD, PhD, University of Calgary, Calgary, AB, Canada, discusses how immune deregulation can be used to predict response to cellular therapies and immunotherapies, such as CAR T-cell products and monocloncal antibodies. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Paola Neri

Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level 7:13
Circulating malignant plasma cell biology in HRMM: detecting PR cells at the single cell level
Gareth Morgan et al. • 23 Oct 2025
Understanding mechanisms of resistance to targeted therapies in myeloma
Charlotte Pawlyn et al. • 3 May 2024
Using the available repertoire of bispecific antibodies for treating multiple myeloma 1:45
Using the available repertoire of bispecific antibodies for treating multiple myeloma
Paola Neri • 17 Feb 2024
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma 1:20
Antigen loss as a key driver of resistance to anti-BCMA T-cell therapies in myeloma
Paola Neri • 17 Feb 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals